Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Inflammation, Malaise, Mobility decreased, Pyrexia
Clinical narrative: could not eat; not feeling well; Inflammation; sick; exposed to covid; could not move; Fever; This spontaneous case was reported by a consumer and describes the occurrence of MOBILITY DECREASED (could not move), PYREXIA (Fever), FEEDING DISORDER (could not eat), MALAISE (not feeling well) and INFLAMMATION (Inflammation) in a 19-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031H21A, 028A21A and 045B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    no known allergies.  Concurrent medical conditions included Asthma chronic (almost died from), Non-smoker and Abstains from alcohol.   In December 2015, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram every two weeks. In February 2021, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to 40 milligram every two weeks and ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose every two weeks. On 27-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In August 2021, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose every two weeks. On 20-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In December 2021, the patient experienced MOBILITY DECREASED (could not move) and PYREXIA (Fever). On an unknown date, the patient experienced FEEDING DISORDER (could not eat), MALAISE (not feeling well), INFLAMMATION (Inflammation), ILLNESS (sick) and EXPOSURE TO SARS-COV-2 (exposed to covid). In December 2021, MOBILITY DECREASED (could not move) and PYREXIA (Fever) had resolved. In January 2022, FEEDING DISORDER (could not eat) had resolved. At the time of the report, MALAISE (not feeling well), INFLAMMATION (Inflammation) and ILLNESS (sick) had resolved and EXPOSURE TO SARS-COV-2 (exposed to covid) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2021, Body temperature: 102.7 102.7 F. On an unknown date, Blood test: Normal.         Concomitant product use was not provided by the reporter.  Action taken was dose increased wit respect to the event could not eat and unknown with respect to all the other events with respect to ADALIMUMAB (HUMIRA).  Treatment information was not provided.  The reporter's causality for the events of could not eat and patient had exposed to covid was not provided, not feeling well, inflammation, sick was no reasonable and fever was reasonable possibility with HUMIRA 40MG/0.4ML(ADALIMUMAB).  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2022-625949, MOD-2022-626070 (Patient Link).   Reporter did not allow further contact